Key factors
sym | TTOO |
exch | US |
MCap | 15.43M |
Beta | 0.132 |
EPS | -35.6 |
Div date | 0000-00-00 |
Yesterday
sym | TTOO |
exch | US |
close | 2.99 |
50 Day MA | 4.336 |
200 Day MA | 12.32 |
52 Week High | 70.0 |
52 Week Low | 2.7 |
Target Price | 12.0 |
Market Cap Mln | 15.43 |
Share statistics
Shares Outstanding | 4932.46K |
Shares Float | 3353.36K |
Percent Institutions | 21.54 |
PercentInsiders | 7.549 |
SharesShort | 396.90K |
Short Ratio | 2.14 |
Shares Short Prior Month | 295.39K |
Short Percent | 7.190 |
Income
Revenue TTM | 10.99M |
Revenue Per Share TTM | 7.933 |
Quarterly Revenue Growth YOY | -60.0 |
Gross Profit TTM | -24.7M |
EBITDA | -46.1M |
Diluted Eps TTM | -35.6 |
earning
Operating Margin TTM | -7.53 |
EPS Estimate Current Quarter | -2.2 |
EPS Estimate Current Year | -18.5 |
EPS Estimate Next Year | -6.36 |
Earnings Share | -35.6 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 2023-10-13 |
Last Split Factor | 1:100 |
business
Enterprise Value Ebitda | -1.16 |
Enterprise Value Revenue | 7.114 |
Book Value /share | -4.90 |
Price Book MRQ | 14.50 |
Price Sales TTM | 1.403 |
ReturnOnAssetsTTM | -0.67 |
ReturnOnEquityTTM | -6.22 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Diagnostics & Research |
Sector | Healthcare |
Codes
ISIN | US89853L1044 |
CIK | 1492674 |
Code | TTOO |
CUSIP | 89853L104 |
Employer Id Number | 20-4827488 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-12 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 158.0 |
IPODate | 2014-08-07 |
International Domestic | Domestic |
MostRecent Quarter | 2024-03-31 |
Contact
Name | T2 Biosystms Inc |
Address | 101 Hartwell Avenue, Lexington, MA, United States, 02421 |
Country Name | USA |
Phone | 781 761 4646 |
Web URL | https://www.t2biosystems.com |
Logo URL | /img/logos/US/TTOO.png |
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.